Nasdaq 100 Stocks SEC Filings — March 18, 2026

18-03-2026

18-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 18, 2026, announcing the issuance of a press release titled 'AITX's RAD Unveils Rebuilt radsecurity.com'. The press release is attached as Exhibit 99.1 under Item 9.01. The filing is furnished under Item 8.01 and not deemed filed for liability purposes.

18-03-2026

Faraday Future Intelligent Electric Inc. announced an executive and employee share purchase initiative, where deferred compensation for March 1 to May 31, 2026, estimated at approximately $500,000 after-tax, will be used to repurchase Class A common stock, subject to board approval, securities laws, and trading policies. The repurchased shares will be transferred to participants to settle the deferred amounts, aiming to align interests with stockholders, support liquidity management, and counter potential illegal market manipulation and short selling. This follows the company's commitment to strategic execution amid capital markets volatility.

• ·Filing date: March 18, 2026; Event date: March 17, 2026
• ·Principal executive offices: 18455 S. Figueroa Street, Gardena, CA 90248
• ·Company preparing potential SEC submission regarding illegal market manipulation

18-03-2026

Micron Technology reported record Q2 FY2026 revenue of $23.86B, up 75% QoQ from $13.64B and 196% YoY from $8.05B, with GAAP net income of $13.79B ($12.07 diluted EPS) and non-GAAP net income of $14.02B ($12.20 EPS). All business units showed strong growth, with gross margins reaching 74.4% GAAP (74.9% non-GAAP) and operating cash flow of $11.90B. The company raised its quarterly dividend 30% to $0.15/share and guided Q3 revenue to $33.5B ±$0.75B with ~81% gross margins.

• ·Q2 FY2026 GAAP gross margin of $17.755B (74.4% of revenue), up from 56.0% QoQ and 36.8% YoY.
• ·Investments in capital expenditures, net: $5.0B for Q2 FY2026.
• ·Quarterly dividend of $0.15 per share, payable April 15, 2026 to shareholders of record March 30, 2026.
• ·Cash and equivalents: $13.908B as of Feb 26, 2026.
• ·Total assets: $101.509B as of Feb 26, 2026.

18-03-2026

Critical Metals Corp., a foreign private issuer focused on critical metals mining including the Wolfsberg Lithium Project in Austria and Tanbreez Rare Earth Project in Greenland, filed a Form F-3 shelf registration statement with the SEC on March 18, 2026, to potentially offer unspecified securities in the future. The prospectus incorporates by reference the company's Annual Report on Form 20-F for the fiscal year ended June 30, 2025 (filed October 6, 2025, amended October 15, 2025) and multiple Form 6-K reports from 2025 and 2026. No specific offering amounts or financial metrics are detailed in the filing.

• ·Business Combination closing date: February 27, 2024
• ·Agreement to acquire interest in Tanbreez Project announced: June 5, 2024
• ·Former name: Critical Metals Ltd (name change: October 18, 2022)
• ·Wolfsberg Project location: Carinthia, Austria, approximately 270 kilometers south of Vienna
• ·Incorporated reports include Form 6-Ks furnished on dates such as March 28, 2025; July 10, 2025; September 29, 2025; and up to March 13, 2026

18-03-2026

Creative Media & Community Trust Corporation (CMCT) filed an 8-K/A to disclose the number of Common Stock shares issued to satisfy Preferred Stock redemptions initiated prior to March 5, 2026, and those noticed on March 6, 2026. On March 12, 2026, the Company issued 1,106,594 Common shares for Series A Preferred redemptions and 2,322,421 for Series A1 Preferred redemptions; on March 16, 2026, it issued 51,027,328 for Series A, 206,166,177 for Series A1, and 594,090 for Series D Preferred redemptions, based on 20-day VWAP preceding each date. These issuances, totaling over 261 million Common shares, were exempt under Section 3(a)(9) of the Securities Act and may dilute existing shareholders.

• ·Redemptions satisfied on March 12, 2026 for all Preferred Stock holder requests prior to March 5, 2026.
• ·Issuances exempt from registration under Section 3(a)(9) of the Securities Act of 1933.
• ·Common Stock trading symbol: CMCT on Nasdaq.

18-03-2026

At Pineapple Financial Inc.'s 2026 Annual Meeting of Stockholders on March 13, 2026, shareholders elected six directors—Shubha Dasgupta, Kendall Marin, Drew Green, Paul Baron, Tasis Giannoukakis, and Anthony Georgiades—each receiving majority support ranging from approximately 79% (Dasgupta and Georgiades) to 91% (others). Shareholders also ratified MNP LLP as the independent auditors for the fiscal year ending August 31, 2026, with 86.8% votes in favor (2,709,116.09 shares). While all proposals passed decisively, Dasgupta and Georgiades faced relatively higher opposition with around 180,000 votes against each.

• ·Meeting results filed on March 18, 2026
• ·Company is an emerging growth company
• ·Common Shares traded as PAPL on NYSE American

18-03-2026

Evolution Metals & Technologies Corp. (EM&T, NASDAQ: EMAT), formerly Welsbach Technology Metals Acquisition Corp., released a corporate video on March 18, 2026, showcasing its current commercial operations including production of sintered magnets, bonded magnets, and mid-stream critical minerals processing. The video is available on the company's investor relations website at https://evolution-metals.com/investor-relations/media. This information is furnished under Item 7.01 and not deemed filed.

18-03-2026

MetaVia Inc. announced IRB approval from Clinical Pharmacology of Miami for its Phase 1 Part 3 clinical trial of lead asset DA-1726, a novel dual oxyntomodulin analog agonist targeting GLP-1 and glucagon receptors. The trial will enroll 40 obese adults across two parts (20 per part, randomized 4:1 active:placebo), evaluating safety, tolerability, PK, pharmacodynamics, and endpoints like weight loss and cardiometabolic measures via one-step (16mg/48mg) and two-step (16mg/32mg/64mg) titration regimens. Initial dosing is planned for April 2026, with data expected in Q4 2026.

• ·Part 3A: one-step titration with 16 mg for 4 weeks followed by 48 mg for 12 weeks
• ·Part 3B: two-step titration with 16 mg for 4 weeks, 32 mg for 4 weeks, and 64 mg for 8 weeks
• ·Primary endpoints: adverse events, serious adverse events, treatment-emergent adverse events, AEs leading to discontinuation
• ·Secondary/exploratory endpoints: PK, metabolic/glycemic/lipid/body composition measures including weight, waist circumference, BMI, cardiometabolic measures

18-03-2026

CTBI's DEF 14A proxy statement, filed March 18, 2026, details board governance, committee structures, and 2025 activities, including a policy prohibiting directors and executives from hedging or pledging significant CTBI equity securities (lesser of 1% outstanding or 50% owned). The Board held 6 meetings in 2025, with all directors attending at least 75% of Board and committee meetings and the 2025 Annual Meeting. Independent committees such as Audit (chaired by Eugenia Crittenden “Crit” Luallen, audit financial expert), Compensation, Nominating, Risk and Compliance oversee key risks and functions via enterprise-wide risk management.

• ·All Audit Committee members meet Nasdaq independence and qualifications standards.
• ·Compensation Committee met twice in 2025.
• ·Nominating and Corporate Governance Committee met twice in 2025.
• ·Risk and Compliance Committee met four times in 2025 and receives quarterly risk reports.
• ·Enterprise-wide risk management (EWRM) overseen by Board committees including Audit and Risk and Compliance.

18-03-2026

ImmuCell Corporation (Nasdaq: ICCC) appointed Kathy Turner, former Elanco Animal Health board member and IDEXX Laboratories executive, to its Board of Directors effective April 1, 2026, replacing Steven Rosgen who is retiring after 8 years of service since January 2018. Turner will serve as Chair of the Compensation and Stock Option Committee and a member of the Audit Committee, bringing over 30 years of experience in healthcare and animal health. No financial metrics or impacts were disclosed in the announcement.

• ·Kathy Turner previously served on the Board of Directors of Elanco Animal Health.
• ·At IDEXX Laboratories, Turner was Chief Marketing Officer and Senior Vice President of International Operations, contributing to double-digit growth in international markets.
• ·Turner currently serves on the Board of Veterinarians Without Borders.
• ·Contacts: investor.relations@immucell.com and iccc@lythampartners.com